380 reports of this reaction
1.3% of all LIFITEGRAST reports
#15 most reported adverse reaction
EYE DISCHARGE is the #15 most commonly reported adverse reaction for LIFITEGRAST, manufactured by Bausch & Lomb Incorporated. There are 380 FDA adverse event reports linking LIFITEGRAST to EYE DISCHARGE. This represents approximately 1.3% of all 29,776 adverse event reports for this drug.
Patients taking LIFITEGRAST who experience eye discharge should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE DISCHARGE is a less commonly reported adverse event for LIFITEGRAST, but still significant enough to appear in the safety profile.
In addition to eye discharge, the following adverse reactions have been reported for LIFITEGRAST:
The following drugs have also been linked to eye discharge in FDA adverse event reports:
EYE DISCHARGE has been reported as an adverse event in 380 FDA reports for LIFITEGRAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE DISCHARGE accounts for approximately 1.3% of all adverse event reports for LIFITEGRAST, making it a notable side effect.
If you experience eye discharge while taking LIFITEGRAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.